Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

760 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS. Nava Rodrigues D, et al. Among authors: scher h. J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4. J Clin Invest. 2018. PMID: 30179225 Free PMC article. Clinical Trial.
Introduction: prostate cancer.
Scher HI. Scher HI. Semin Oncol. 1994 Oct;21(5):511-3. Semin Oncol. 1994. PMID: 7939744 No abstract available.
Differential exoprotease activities confer tumor-specific serum peptidome patterns.
Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Villanueva J, et al. Among authors: scher hi. J Clin Invest. 2006 Jan;116(1):271-84. doi: 10.1172/JCI26022. J Clin Invest. 2006. PMID: 16395409 Free PMC article.
Improved prediction of prostate cancer recurrence through systems pathology.
Cordon-Cardo C, Kotsianti A, Verbel DA, Teverovskiy M, Capodieci P, Hamann S, Jeffers Y, Clayton M, Elkhettabi F, Khan FM, Sapir M, Bayer-Zubek V, Vengrenyuk Y, Fogarsi S, Saidi O, Reuter VE, Scher HI, Kattan MW, Bianco FJ, Wheeler TM, Ayala GE, Scardino PT, Donovan MJ. Cordon-Cardo C, et al. J Clin Invest. 2007 Jul;117(7):1876-83. doi: 10.1172/JCI31399. J Clin Invest. 2007. PMID: 17557117 Free PMC article.
Targeting the androgen receptor pathway in prostate cancer.
Chen Y, Sawyers CL, Scher HI. Chen Y, et al. Curr Opin Pharmacol. 2008 Aug;8(4):440-8. doi: 10.1016/j.coph.2008.07.005. Epub 2008 Aug 12. Curr Opin Pharmacol. 2008. PMID: 18674639 Free PMC article. Review.
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Tran C, et al. Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9. Science. 2009. PMID: 19359544 Free PMC article. Clinical Trial.
760 results